ABOUT QURETECH BIO

QureTech Bio’s vision is to develop first-line drugs to combat infectious diseases and the occurrence of antibiotic resistance.

QureTech Bio was founded in 2010 to commercialize world-leading research from groups based at Umeå University, Sweden, and Washington University, St Louis, USA. Since the foundation, several key persons have joined the company either as board members, researchers, or scientific advisors.

The company’s development programs are based on research mainly funded by academic research grants. The company has also received soft funding from Umeå Biotech Incubator and the European Union Horizon 2020 program SME Instrument Phase 1.

Infographic: Quretech Bio wants to combat infectious diseases

MANAGEMENT TEAM

Helén Fält
CEO

Fredrik Almqvist
Research director

Sven Bergström
Chairman

Annica Rönnbäck
Coordinator

Jörgen Johansson
Co-founder

BOARD OF DIRECTORS

Sven Bergström
Chairman of the board

Christina Stallings
Vice chairman

Jörgen Johansson
Deputy board member

Scott Hultgren
Deputy board member/CSO

BUSINESS ADVISORY BOARD

Karin Meyer
Apotekarsocieteten

Lars Gunneflo
Life Science Consultant

SCIENTIFIC TEAM

Michael Caparon
Professor

Ana Flores-Mireles
Assistant Professor

Björn Olsen
Professor

Mari Bonde
PhD

Matthew Chapman
Professor

Jerry Pinkner
M.S.